WuXi, BioNTech sign deal for monoclonal antibody discovery

Thomas Lohnes/Getty Images News WuXi Biologics said it has signed a research agreement with BioNTech ( NASDAQ: BNTX ) for the discovery of monoclonal antibodies for potential development into therapeutic products. Under the deal, WuXi will utilize its proprietary antibody discovery platforms to discover two undisclosed targets of preclinical antibodies for BioNTech to develop into potential therapies.

BioNTech will be granted exclusive rights to the investigational antibodies. In exchange, WuXi will receive $20M upfront and will be eligible to receive milestone payments plus tiered royalties on any product sales, according to WuXi . More on BioNTech BioNTech SE (BNTX) 42nd Annual J.P. Morgan Healthcare Conference (Transcript) BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics BioNTech's COVID 19 Success Paves The Way For A Strong Drug Pipeline BioNTech sets 2024 outlook below consensus Masking returns to some U.S.

hospitals amid rising COVID, flu cases.